SLRN: Acelyrin, Inc. Stock

by  •  • Comments Off on SLRN: Acelyrin, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 596.85
Enterprise Value ($M) 380.53
Book Value ($M) 528.28
Book Value / Share 5.29
Price / Book 1.13
NCAV ($M) 506.56
NCAV / Share 5.08
Price / NCAV 1.18

Profitability (mra)
Return on Invested Capital (ROIC) -0.49
Return on Assets (ROA) -0.33
Return on Equity (ROE) -0.33

Liquidity (mrq)
Quick Ratio 7.15
Current Ratio 7.15

Balance Sheet (mrq) ($M)
Current Assets 596.59
Assets 618.31
Liabilities 90.03
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
1 day ago 13G/A T. Rowe Price Investment Management, Inc. 10.50 -0.64
3 days ago 13G/A Vanguard Group Inc 4.07 0.00
7 days ago 13G BlackRock, Inc. 6.00 0.00
08-12 13G/A Fmr Llc 3.92 -55.97
05-20 13G Integrated Core Strategies (us) Llc 5.20 4.75
03-28 13G AyurMaya Capital Management Company, LP 9.60
02-14 13G/A Citadel Advisors Llc 6.80

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-14 175,751 1,149,449 15.29
2024-11-13 56,290 311,478 18.07
2024-11-12 59,576 243,242 24.49
2024-11-11 23,097 201,978 11.44

(click for more detail)

Similar Companies
SCPH – scPharmaceuticals Inc. SDGR – Schrödinger, Inc.
SLDB – Solid Biosciences Inc. SNDX – Syndax Pharmaceuticals, Inc.
SPRO – Spero Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io